Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emanuela Pesce

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Journal of Medicinal Chemistry|July 13, 2023
Innovative Strategy toward Mutant CFTR Rescue in Cystic Fibrosis: Design and Synthesis of Thiadiazole Inhibitors of the E3 Ligase RNF5Irene Brusa, Elvira Sondo, Emanuela Pesce, et al.
Science Advances|March 5, 2020
Discovery of a picomolar potency pharmacological corrector of the mutant CFTR chloride channelNicoletta Pedemonte, Fabio Bertozzi, Emanuela Caci, et al.
Scientific Reports|July 18, 2015
Genetic Inhibition Of The Ubiquitin Ligase Rnf5 Attenuates Phenotypes Associated To F508del Cystic Fibrosis MutationValeria Tomati, Elvira Sondo, Andrea Armirotti, et al.
International Journal of Molecular Sciences|March 25, 2022
The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating DrugsElvira Sondo, Federico Cresta, Cristina Pastorino, et al.
European Journal of Medicinal Chemistry|September 10, 2025
Developing Type II F508del-CFTR correctors with a protective effect against respiratory virusesFrancesca Barbieri, Maria Grazia Martina, Emanuela Pesce, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 21, 2022
Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell backgroundValeria Tomati, Stefano Costa, Valeria Capurro, et al.
ERJ Open Research|May 28, 2025
Deleterious effect of <i>Pseudomonas aeruginosa</i> on F508del-CFTR rescued by elexacaftor/tezacaftor/ivacaftor is clinical strain-dependent in patient-derived nasal cellsCaterina Allegretta, Enza Montemitro, Maria Noemi Sgobba, et al.
American Journal of Respiratory Cell and Molecular Biology|July 16, 2024
Investigation of CFTR Function in Human Nasal Epithelial Cells Informs Personalized MedicineAudrey Pion, Erin Kavanagh, Anya T Joynt, et al.
Plos One|September 8, 2011
Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemiaFrancesco Maura, Giovanna Cutrona, Sonia Fabris, et al.
Frontiers in Pharmacology|December 3, 2024
Pharmacological rescue of the G85E CFTR variant by preclinical and approved modulatorsValeria Tomati, Valeria Capurro, Emanuela Pesce, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Journal of Medicinal Chemistry|July 13, 2023
Innovative Strategy toward Mutant CFTR Rescue in Cystic Fibrosis: Design and Synthesis of Thiadiazole Inhibitors of the E3 Ligase RNF5Irene Brusa, Elvira Sondo, Emanuela Pesce, et al.
Science Advances|March 5, 2020
Discovery of a picomolar potency pharmacological corrector of the mutant CFTR chloride channelNicoletta Pedemonte, Fabio Bertozzi, Emanuela Caci, et al.
Scientific Reports|July 18, 2015
Genetic Inhibition Of The Ubiquitin Ligase Rnf5 Attenuates Phenotypes Associated To F508del Cystic Fibrosis MutationValeria Tomati, Elvira Sondo, Andrea Armirotti, et al.
International Journal of Molecular Sciences|March 25, 2022
The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating DrugsElvira Sondo, Federico Cresta, Cristina Pastorino, et al.
European Journal of Medicinal Chemistry|September 10, 2025
Developing Type II F508del-CFTR correctors with a protective effect against respiratory virusesFrancesca Barbieri, Maria Grazia Martina, Emanuela Pesce, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 21, 2022
Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell backgroundValeria Tomati, Stefano Costa, Valeria Capurro, et al.
ERJ Open Research|May 28, 2025
Deleterious effect of <i>Pseudomonas aeruginosa</i> on F508del-CFTR rescued by elexacaftor/tezacaftor/ivacaftor is clinical strain-dependent in patient-derived nasal cellsCaterina Allegretta, Enza Montemitro, Maria Noemi Sgobba, et al.
American Journal of Respiratory Cell and Molecular Biology|July 16, 2024
Investigation of CFTR Function in Human Nasal Epithelial Cells Informs Personalized MedicineAudrey Pion, Erin Kavanagh, Anya T Joynt, et al.
Plos One|September 8, 2011
Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemiaFrancesco Maura, Giovanna Cutrona, Sonia Fabris, et al.
Frontiers in Pharmacology|December 3, 2024
Pharmacological rescue of the G85E CFTR variant by preclinical and approved modulatorsValeria Tomati, Valeria Capurro, Emanuela Pesce, et al.
Pageof 5